ICOS and Autoimmunity: The combined use of CTLA4Ig and anti‐ICOS mAb in our model was far superior in blocking primary CD4+ T‐cell responses, suggesting this dual targeting may have significantly enhanced clinical benefit in treating autoimmunity and graft rejection.